The performance of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the expiry in key territories has introduced considerable volatility. Investors are now facing the impact of lower-cost altern